Document is current
Any future updates will be listed below
-
Authors
Rajendran, Jayasimman
Purhonen, Janne
Tegelberg, Saara
Smolander, Olli‐Pekka
Mörgelin, Matthias
Rozman, Jan
Gailus‐Durner, Valerie
Fuchs, Helmut
Hrabe de Angelis, Martin
Auvinen, Petri
Mervaala, Eero
Jacobs, Howard T
Szibor, Marten
Fellman, Vineta
Kallijärvi, Jukka https://orcid.org/0000-0003-3773-7025
-
Funding
Funding for this research was provided by:
Academy of Finland (259296)
Academy of Finland (272376)
Vetenskapsrådet (521‐2011‐3877)
European Research Council (232738)
Finska Läkaresällskapet
Lastentautien Tutkimussäätiö
German Federal Ministry of Education and Research (01KX1012)
Folkhälsan Research Center
- License Information
-
More Information
Article History
Received: 8 August 2018
Revised: 8 November 2018
Accepted: 12 November 2018
First Online: 10 December 2018
Conflict of interest
: MS is a shareholder of a commercial enterprise that is dedicated to developing therapeutics based on AOX. The authors declare that they have no conflict of interest.
